A Fully Automated High-Throughput Zebrafish Behavioral Ototoxicity Assay

Todd, Douglas Wallace; Philip, Rohit C.; Niihori, Maki; Ringle, Ryan A; Coyle, Kelsey R; Zehri, Sobia F; Zabala, Leanne; Mudery, Jordan A.; Francis, Ross H.; Rodríguez, Jeffrey J.; Jacob, Abraham

doi:10.1089/zeb.2016.1412

Cited by 24 publications

(18 citation statements)

References 52 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…33,35,36 In the studies dedicated to apocynin, L-Serine, CHCP1, Rapamycin, Sal B, KR-22335, ORC-13661, ATX, NAC, CYM-5478, and curcuminoids zebrafish served as a second model in addition to mice, guinea pig, cancer cell lines and HEI-OC1 mouse cell line derived from the organ of Corti. 17,20,27,28,30,35,[38][39][40] The details regarding the experimental design for otoprotective screening are summarized in Table 2.…”

Section: Experimental Protocolsmentioning

confidence: 99%

Use of zebrafish larvae lateral line to study protection against cisplatin-induced ototoxicity: A scoping review

Domarecka

Skarzynska

Szczepek

et al. 2020

Int J Immunopathol Pharmacol

View full text Add to dashboard Cite

Aim: The present review aimed to consolidate and analyze the recent information about the use of zebrafish in studies concerning cisplatin-induced ototoxicity and otoprotection. Material and methods: The PubMed, Web of Science, and Scopus databanks were searched using the following MESH terms: zebrafish, cisplatin, ototoxicity. The identified publications were screened according to inclusion and exclusion criteria and the 26 qualifying manuscripts were included in the full-text analysis. The experimental protocols, including cisplatin concentrations, the exposure duration and the outcome measurements used in zebrafish larvae studies, were evaluated and the reported knowledge was summarized. Results: Twenty-six substances protecting from cisplatin-induced toxicity were identified with the use of zebrafish larvae. These substances include quinine, salvianolic acid B, berbamine 6, benzamil, quercetin, dexmedetomidine, dexamethsanone, quinoxaline, edaravone, apocynin, dimethyl sulfoxide, KR-22335, SRT1720, ORC-13661, 3-MA, D-methionine, mdivi-1, FUT-175, rapamycin, Z-LLF-CHO, ATX, NAC, CYM-5478, CHCP1, CHCP2 and leupeptin. The otoprotective effects of compounds were attributed to their anti-ROS, anti-apoptotic and cisplatin uptake-blocking properties. The broadest range of protection was achieved when the experimental flow used preconditioning with an otoprotective compound and later a co-incubation with cisplatin. Protection against a high concentration of cisplatin was observed only in protocols using short exposure times (4 and 6 h). Conclusions: The data extracted from the selected papers confirm that despite the differences between the human and the zebra fish hearing thresholds (as affected by cisplatin), the sensory cells of zebrafish and larval zebrafish are a valuable tool which could be used: (i) for the discovery of novel otoprotective substances and compounds; (ii) to screen their side effects and (iii) to extend the knowledge on the mechanisms of cisplatin-induced inner ear damage. For future studies, the development of a consensus experimental protocol is highly recommended.

show abstract

Section: Experimental Protocolsmentioning

confidence: 99%

Use of zebrafish larvae lateral line to study protection against cisplatin-induced ototoxicity: A scoping review

Domarecka

Skarzynska

Szczepek

et al. 2020

Int J Immunopathol Pharmacol

View full text Add to dashboard Cite

show abstract

“…The development of non-ototoxic drugs may be facilitated by the biological screening of hair cell damage, either in vivo via high-throughput screening of zebrafish or in vitro via effects on cultured hair cells. 68…”

Section: Advances In Bioscience: Implications For Otologymentioning

confidence: 99%

The future of otology

Jackler

Jan

2019

J. Laryngol. Otol.

View full text Add to dashboard Cite

BackgroundThe field of otology is increasingly at the forefront of innovation in science and medicine. The inner ear, one of the most challenging systems to study, has been rendered much more open to inquiry by recent developments in research methodology. Promising advances of potential clinical impact have occurred in recent years in biological fields such as auditory genetics, ototoxic chemoprevention and organ of Corti regeneration. The interface of the ear with digital technology to remediate hearing loss, or as a consumer device within an intelligent ecosystem of connected devices, is receiving enormous creative energy. Automation and artificial intelligence can enhance otological medical and surgical practice. Otology is poised to enter a new renaissance period, in which many previously untreatable ear diseases will yield to newly introduced therapies.ObjectiveThis paper speculates on the direction otology will take in the coming decades.ConclusionMaking predictions about the future of otology is a risky endeavour. If the predictions are found wanting, it will likely be because of unforeseen revolutionary methods.

show abstract

“…Species‐specific differences in organ tolerance require various cisplatin doses, schedules, and routes of administration. Recently, the zebrafish has emerged as a novel model for this purpose . Agents showing otoprotection must be screened for potential interference with cisplatin chemotherapy effects.…”

Section: Challenges In Preventing Cihlmentioning

confidence: 99%

“…Recently, the zebrafish has emerged as a novel model for this purpose. 40 Agents showing otoprotection must be screened for potential interference with cisplatin chemotherapy effects. This may be performed using in vitro cancer cell cytotoxicity assays, but generally requires tumor xenograft studies using nude mouse models.…”

Section: Preclinical Models For Identifying Otoprotective Agentsmentioning

confidence: 99%

Prevention of cisplatin‐induced hearing loss in children: Informing the design of future clinical trials

et al. 2018

View full text Add to dashboard Cite

Cisplatin is an essential chemotherapeutic agent in the treatment of many pediatric cancers. Unfortunately, cisplatin‐induced hearing loss (CIHL) is a common, clinically significant side effect with life‐long ramifications, particularly for young children. ACCL05C1 and ACCL0431 are two recently completed Children’s Oncology Group studies focused on the measurement and prevention of CIHL. The purpose of this paper was to gain insights from ACCL05C1 and ACCL0431, the first published cooperative group studies dedicated solely to CIHL, to inform the design of future pediatric otoprotection trials. Use of otoprotective agents is an attractive strategy for preventing CIHL, but their successful development must overcome a unique constellation of methodological challenges related to translating preclinical research into clinical trials that are feasible, evaluate practical interventions, and limit risk. Issues particularly important for children include use of appropriate methods for hearing assessment and CIHL severity grading, and use of trial designs that are well‐informed by preclinical models and suitable for relatively small sample sizes. Increasing interest has made available new funding opportunities for expanding this urgently needed research.

show abstract

A Fully Automated High-Throughput Zebrafish Behavioral Ototoxicity Assay

Cited by 24 publications

References 52 publications

Use of zebrafish larvae lateral line to study protection against cisplatin-induced ototoxicity: A scoping review

Use of zebrafish larvae lateral line to study protection against cisplatin-induced ototoxicity: A scoping review

The future of otology

Prevention of cisplatin‐induced hearing loss in children: Informing the design of future clinical trials

Contact Info

Product

Resources

About